Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1040470/000165495420009618/aehr_10k.htm
April 2022
March 2022
January 2022
January 2022
January 2022
October 2021
October 2021
September 2021
September 2021
July 2021
Aehr
Test Systems
|
MKR
Investor Relations Inc.
|
Ken
Spink
|
Todd Kehrli or Jim
Byers
|
Chief Financial
Officer
|
Analyst/Investor
Contact
|
(510) 623-9400
x309
|
(323)
468-2300
|
|
aehr@mkr-group.com
|
|
Three Months
Ended
|
Year
Ended
|
|||
|
May
31,
|
Feb
29,
|
May
31,
|
May
31,
|
May
31,
|
|
2020
|
2020
|
2019
|
2020
|
2019
|
|
|
|
|
|
|
Net
sales
|
$3,773
|
$6,111
|
$7,242
|
$22,291
|
$21,056
|
Cost of
sales
|
3,866
|
3,120
|
3,863
|
13,920
|
13,454
|
Gross (loss)
profit
|
(93)
|
2,991
|
3,379
|
8,371
|
7,602
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
Selling,
general and administrative
|
1,674
|
1,891
|
2,018
|
7,530
|
7,724
|
Research
and development
|
854
|
845
|
1,120
|
3,386
|
4,153
|
Restructuring
|
220
|
-
|
118
|
220
|
725
|
Total
operating expenses
|
2,748
|
2,736
|
3,256
|
11,136
|
12,602
|
|
|
|
|
|
|
(Loss)
income from operations
|
(2,841)
|
255
|
123
|
(2,765)
|
(5,000)
|
|
|
|
|
|
|
Interest (expense)
income, net
|
(17)
|
13
|
(24)
|
10
|
(252)
|
Other (expense)
income, net
|
(17)
|
(9)
|
17
|
(11)
|
44
|
|
|
|
|
|
|
(Loss)
income before income tax expense
|
(2,875)
|
259
|
116
|
(2,766)
|
(5,208)
|
|
|
|
|
|
|
Income tax
expense
|
(10)
|
(14)
|
(6)
|
(36)
|
(27)
|
|
|
|
|
|
|
Net
(loss) income
|
(2,885)
|
245
|
110
|
(2,802)
|
(5,235)
|
|
|
|
|
|
|
Less: Net income
attributable to the
|
|
|
|
|
|
noncontrolling
interest
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
Net
(loss) income attributable to Aehr Test
|
|
|
|
|
|
Systems
common shareholders
|
$(2,885)
|
$245
|
$110
|
$(2,802)
|
$(5,235)
|
|
|
|
|
|
|
Net (loss) income
per share
|
|
|
|
|
|
Basic
|
$(0.13)
|
$0.01
|
$0.00
|
$(0.12)
|
$(0.23)
|
Diluted
|
$(0.13)
|
$0.01
|
$0.00
|
$(0.12)
|
$(0.23)
|
|
|
|
|
|
|
Shares used in per
share calculations:
|
|
|
|
|
|
Basic
|
23,060
|
22,937
|
22,605
|
22,882
|
22,387
|
Diluted
|
23,060
|
23,130
|
22,717
|
22,882
|
22,387
|
|
Three Months
Ended
|
Year
Ended
|
|||
|
May
31,
|
Feb
29,
|
May
31,
|
May
31,
|
May
31,
|
|
2020
|
2020
|
2019
|
2020
|
2019
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net (loss)
income
|
$(2,885)
|
$245
|
$110
|
$(2,802)
|
$(5,235)
|
Stock-based
compensation expense
|
300
|
207
|
200
|
910
|
905
|
Restructuring
|
220
|
-
|
118
|
220
|
725
|
Excess and
obsolescence provision
|
1,645
|
-
|
-
|
1,645
|
795
|
Non-GAAP net (loss)
income
|
$(720)
|
$452
|
$428
|
$(27)
|
$(2,810)
|
|
|
|
|
|
|
GAAP net (loss)
income per diluted share
|
$(0.13)
|
$0.01
|
$0.00
|
$(0.12)
|
$(0.23)
|
Non-GAAP net (loss)
income per diluted share
|
$(0.03)
|
$0.02
|
$0.02
|
$(0.00)
|
$(0.13)
|
Shares used in GAAP
diluted shares calculation
|
23,060
|
23,130
|
22,717
|
22,882
|
22,387
|
Shares used in
non-GAAP diluted shares calculation
|
23,060
|
23,130
|
22,717
|
22,882
|
22,387
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP
net (loss) income is a non-GAAP measure and should not be
considered a replacement for GAAP results. Non-GAAP net (loss)
income is a financial measure the Company uses to evaluate the
underlying results and operating performance of the business. The
limitation of this measure is that it excludes items that impact
the Company's current period net income. This limitation is best
addressed by using this measure in combination with net (loss)
income (the most directly comparable GAAP financial measure). These
measures are not in accordance with GAAP and may differ from
non-GAAP methods of accounting and reporting used by other
companies.
We
believe these measures enhance investors’ ability to review
the company’s business from the same perspective as the
company’s management and facilitate comparisons of this
period’s results with prior periods.
|
|
May
31,
|
February
29,
|
May
31,
|
|
2020
|
2020
|
2019
|
ASSETS
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
Cash
and cash equivalents
|
$5,433
|
$5,058
|
$5,428
|
Accounts
receivable, net
|
3,717
|
3,511
|
4,859
|
Inventories
|
7,989
|
9,330
|
9,061
|
Prepaid
expenses and other
|
512
|
586
|
686
|
Total
current assets
|
17,651
|
18,485
|
20,034
|
|
|
|
|
Property and
equipment, net
|
663
|
783
|
1,045
|
Operating lease
right-of-use assets
|
2,107
|
2,260
|
-
|
Other
assets
|
153
|
160
|
228
|
Total
assets
|
$20,574
|
$21,688
|
$21,307
|
|
|
|
|
LIABILITIES
AND SHAREHOLDERS' EQUITY
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
Current
portion of long-term debt
|
$653
|
$-
|
$-
|
Accounts
payable
|
945
|
925
|
1,933
|
Accrued
expenses
|
1,439
|
1,373
|
2,034
|
Operating
lease liabilities, short-term
|
658
|
644
|
-
|
Customer
deposits and deferred revenue, short-term
|
170
|
385
|
1,545
|
Total
current liabilities
|
3,865
|
3,327
|
5,512
|
|
|
|
|
Long-term debt, net
of current portion
|
1,026
|
-
|
-
|
Deferred
rent
|
-
|
-
|
153
|
Operating lease
liabilities, long-term
|
1,605
|
1,772
|
-
|
Deferred revenue,
long-term
|
22
|
34
|
189
|
Total
liabilities
|
6,518
|
5,133
|
5,854
|
|
|
|
|
Aehr Test Systems
shareholders' equity
|
14,077
|
16,575
|
15,472
|
Noncontrolling
interest
|
(21)
|
(20)
|
(19)
|
Total
shareholders' equity
|
14,056
|
16,555
|
15,453
|
|
|
|
|
Total
liabilities and shareholders' equity
|
$20,574
|
$21,688
|
$21,307
|
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1040470/000165495420009618/aehr_10k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Aehr Test Systems.
Aehr Test Systems's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Rating
Learn More![]()
We anticipate that the existing cash balance together with income from operations, collections of existing accounts receivable, revenue from our existing backlog of products, the sale of inventory on hand, deposits and down payments against significant orders, and anticipated loan forgiveness of the PPP Loan will be adequate to meet our liquidity requirements for the next 12 months.
RESTRUCTURING We record a charge for restructuring when management commits to a restructuring plan, the restructuring plan identifies all significant actions, the period of time to complete the restructuring plan indicates that significant changes to the plan are not likely, and individuals who are impacted have been notified of the pending involuntary termination.
Net cash used in operations was also impacted by decreases in customer deposits and deferred revenue of $1.5 million and in accounts payable of $1.0 million, partially offset by decreases in inventories and accounts receivable of $1.2 million each.
The CARES Act includes several significant business tax provisions including modification to the taxable income limitation for utilization of net operating losses (NOLs) incurred in 2018, 2019 and 2020 and the ability to carry back NOLs from those years for a period of up to five years, an increase to the limitation on deductibility of certain business interest expense, bonus depreciation for purchases of qualified improvement property and special deductions on certain corporate charitable contributions.
The decrease in gross profit margin was primarily the result of manufacturing inefficiencies due to a decrease in net sales, product mix, and the impact of reserves taken on excess and obsolete inventory.
The increase in gross profit...Read more
The effect of fluctuation in...Read more
The decrease in SG&A expenses...Read more
Gross profit margin decreased to...Read more
Gross profit margin increased to...Read more
SG&A expenses were $7.7 million...Read more
For the fiscal year ended...Read more
SG&A expenses were $7.5 million...Read more
For employees who are required...Read more
The increase in SG&A expenses...Read more
For employees that are not...Read more
Net sales decreased to $21.1...Read more
Gross profit decreased to $7.6...Read more
We consider revenue to be...Read more
Net cash provided by financing...Read more
The decrease in customer deposits...Read more
The decrease in customer deposits...Read more
The decrease in customer deposits...Read more
For the fiscal year ended...Read more
Restructuring charges for the fiscal...Read more
Restructuring charges for the fiscal...Read more
Restructuring charges for the fiscal...Read more
The increase in inventories is...Read more
The changes were due to...Read more
The increase in accounts receivable...Read more
Uncollectible receivables are recorded as...Read more
While the overall environment remains...Read more
Interest expense decreased to $252,000...Read more
On an ongoing basis, we...Read more
The fair value of each...Read more
R&D expenses were $3.4 million...Read more
Net sales of our wafer-level...Read more
Net sales of our wafer-level...Read more
The decrease was primarily due...Read more
On April 23, 2020, we...Read more
The change in other income...Read more
R&D expenses were flat at...Read more
Net sales increased to $22.3...Read more
The large majority of our...Read more
Net cash used in financing...Read more
Net cash provided by financing...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Aehr Test Systems provided additional information to their SEC Filing as exhibits
Ticker: AEHR
CIK: 1040470
Form Type: 10-K Annual Report
Accession Number: 0001654954-20-009618
Submitted to the SEC: Fri Aug 28 2020 4:01:19 PM EST
Accepted by the SEC: Fri Aug 28 2020
Period: Sunday, May 31, 2020
Industry: Instruments For Meas And Testing Of Electricity And Elec Signals